Literature DB >> 27922863

Suppression of Myocardial 18F-FDG Uptake Through Prolonged High-Fat, High-Protein, and Very-Low-Carbohydrate Diet Before FDG-PET/CT for Evaluation of Patients With Suspected Cardiac Sarcoidosis.

Yang Lu1, Christopher Grant, Karen Xie, Nadera J Sweiss.   

Abstract

BACKGROUND: A major obstacle in using FDG-PET/CT to diagnose cardiac sarcoidosis (CS) is the unpredictable physiological myocardial FDG uptake. We hypothesized that a prolonged 72-hour pretest high-fat, high-protein, and very-low-carbohydrate (HFHPVLC) diet preparation could suppress physiologic myocardial uptake of FDG and thus help to identify active CS.
METHODS: This retrospective study included 215 FDG-PET/CT tests from 207 patients with biopsy-proven sarcoidosis and clinical suspicion for CS between July 2014 and December 2015. The patients were classified into 2 groups. Group 1 included 12 FDG-PET/CT scans from 12 patients who had 24-hour or less pretest HFHPVLC diet preparation. Group 2 included 203 FDG-PET/CT scans with 72-hour HFHPVLC diet before FDG-PET/CT. Nonadherent patients and patients with cancer were excluded. Cardiac FDG uptake was classified as: "none" and "ringlike diffuse at base" (negative for CS), "focal" (positive for CS), and "diffuse" (indeterminate for CS). FDG uptake in myocardial lesions was measured as SUVmax and compared with SUVmean of mediastinal blood pool. Final diagnoses were made with consensus among physicians in view of all available clinical information including cardiac MRI and echocardiogram results.
RESULTS: In group 1, there were 1 (1/12, 8.3%) positive, 5 (5/12, 41.7%) indeterminate, and 6 (6/12, 50.0%) negative for CS. In group 2, 10 patients were excluded (6 patients because of noncompliance with diet, 2 patients with concurrent diagnosis of cancers, 2 patients because of insulin and steroid use within 4 hours before PET/CT); the remaining 185 patients had 193 FDG PET/CT tests (8 repeats), of which there were 19 (19/193, 9.8%) positive, 7 indeterminate (7/193, 3.6%), and 167 (167/193, 86.7.%) negative for CS. The SUVmax of PET-positive myocardial lesions ranges from 3.4 to 12.5, whereas mediastinal blood pool SUVmean ranges from 1.1 to 3.6. The indeterminate rate was significantly lower in group 2 compared with group 1 (P < 0.001).
CONCLUSIONS: The prolonged 72-hour HFHPVLC diet preparation protocol successfully suppressed physiological myocardial FDG uptake and may permit a more sensitive and accurate method of diagnosing active CS using FDG PET/CT.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27922863     DOI: 10.1097/RLU.0000000000001465

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  18 in total

1.  Characterization of a highly effective preparation for suppression of myocardial glucose utilization.

Authors:  Sophia R Larson; Justin A Pieper; Edward A Hulten; Edward P Ficaro; James R Corbett; Venkatesh L Murthy; Richard L Weinberg
Journal:  J Nucl Cardiol       Date:  2019-06-24       Impact factor: 5.952

2.  Optimizing myocardial metabolism for fluorine-18 fluorodeoxyglucose positron emission tomography imaging of cardiac inflammation.

Authors:  Efstathia Andrikopoulou; Pradeep Bhambhvani
Journal:  J Nucl Cardiol       Date:  2017-04-21       Impact factor: 5.952

3.  Importance of extracardiac FDG uptake to diagnose cardiac sarcoidosis.

Authors:  Nobuhiro Tahara; Munehisa Bekki; Yoichi Sugiyama; Atsuko Tahara; Yoshihiro Fukumoto
Journal:  J Nucl Cardiol       Date:  2018-09-05       Impact factor: 5.952

4.  18F-fluorodeoxyglucose use after cardiac transplant: A comparative study of suppression of physiological myocardial uptake.

Authors:  Renata Christian Martins Felix; Clécio Maria Gouvea; Christiane Cigagna Wiefels Reis; Jacqueline Sampaio Dos Santos Miranda; Ligia Beatriz Chaves Espinoso Schtruk; Alexandre Siciliano Colafranceschi; Cláudio Tinoco Mesquita
Journal:  J Nucl Cardiol       Date:  2018-06-14       Impact factor: 5.952

5.  Role of 18F-FDG PET/CT in the diagnosis of cardiovascular implantable electronic device infections: A meta-analysis.

Authors:  Maryam Mahmood; Ayse Tuba Kendi; Saira Farid; Saira Ajmal; Geoffrey B Johnson; Larry M Baddour; Panithaya Chareonthaitawee; Paul A Friedman; M Rizwan Sohail
Journal:  J Nucl Cardiol       Date:  2017-09-14       Impact factor: 5.952

6.  The logic and challenges of imaging sarcoidosis with whole body FDG PET.

Authors:  Roberto C Valentin; Pradeep Bhambhvani
Journal:  J Nucl Cardiol       Date:  2017-08-17       Impact factor: 5.952

Review 7.  The role of positron emission tomography in the assessment of cardiac sarcoidosis.

Authors:  Dario Genovesi; Matteo Bauckneht; Corinna Altini; Cristina Elena Popescu; Paola Ferro; Lavinia Monaco; Anna Borra; Cristina Ferrari; Federico Caobelli
Journal:  Br J Radiol       Date:  2019-06-05       Impact factor: 3.039

8.  FDG PET-CT findings of extra-thoracic sarcoid are associated with cardiac sarcoid: A rationale for using FGD PET-CT for cardiac sarcoid evaluation.

Authors:  Darshan C Patel; Senthil S Gunasekaran; Christopher Goettl; Nadera J Sweiss; Yang Lu
Journal:  J Nucl Cardiol       Date:  2017-07-05       Impact factor: 5.952

9.  Utility of FDG PET and Cardiac MRI in Diagnosis and Monitoring of Immunosuppressive Treatment in Cardiac Sarcoidosis.

Authors:  Richard A Coulden; Emer P Sonnex; Jonathan T Abele; Andrew M Crean
Journal:  Radiol Cardiothorac Imaging       Date:  2020-08-27

Review 10.  Searching for novel PET radiotracers: imaging cardiac perfusion, metabolism and inflammation.

Authors:  Caitlund Q Davidson; Christopher P Phenix; T C Tai; Neelam Khaper; Simon J Lees
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.